PMP22 and Charcot-Marie-Tooth disease type 1A: In conclusion, we developed and characterized an artificial miRNA designed to specifically target human PMP22 and murine Pmp22 transcripts and evaluated the therapeutic benefit in a CMT1A mouse model that reproduces CMT1A-associated phenotypes.